New facility creates greater efficiencies to better meet client needs
KING OF PRUSSIA, PA, Oct. 16 /CNW/ - MDS Pharma Services, a leading
provider of innovative drug-discovery and development solutions, today
announced it has moved its Singapore Global Central Lab operation to a new,
larger facility, enabling the contract research organization to better meet
the current and emerging needs of its clients in the Asia-Pacific region.
Thanks to optimized layout and workflow, the new facility, which is
located in the Marsiling Industrial Park, has twice its previous capacity for
sample storage, processing, and safety testing. Increased capacity was
required to handle both current sample volumes - MDS Pharma Services has seen
its sample volume in Singapore double in the past year - and to meet
anticipated increases in business as a result of growing research investment
in the area.
"MDS Pharma Services has long recognized the importance of investing in
the Asia-Pacific region, and our move to a new laboratory facility in
Singapore - which is becoming a hub of drug-development activity - is a
testament to our commitment to growing across Asia," says MDS Pharma Services
President David Spaight. "We were the first Western contract research
organization to own a facility in China, and the first clinical laboratory
there to receive accreditation from the College of American Pathologists
(CAP). MDS Pharma Services remains at the forefront of the industry with the
resources, expertise and commitment to deliver Quality On-Time(TM) services
for clients in Singapore and the entire Asia-Pacific region."
The Singapore central lab has earned National Glycohemoglobin
Standardization Program (NGSP) Level 1 accreditation, which allows it to
handle diabetes studies conducted under strict international guidelines. It
has also earned CAP accreditation, and recently passed its CAP inspection with
The move further solidifies MDS Pharma Services presence in the
Asia-Pacific region, an area with increasing importance in the
drug-development industry. Since entering the region over a decade ago, MDS
Pharma Services has built a strong staff of clinical development professionals
with expertise in many areas. In addition to central lab services, the
Singapore facility is one of its two Asia-Pacific sites - the other is
Beijing, China - through which MDS Pharma Services offers its industry-leading
integrated centralized cardiac safety services to the entire region. Singapore
is also one of MDS Pharma Services' eight Asian Global Clinical Development
sites that offer late-stage clinical trial monitoring. MDS Pharma Services
offers pharmacology services from its Taipei, Taiwan location.
MDS Pharma Services provides central laboratory services in key
geographic areas around the world, including Singapore, China, Canada, the
United States, France and Germany.
About MDS Pharma Services
MDS Pharma Services is committed to delivering quality service on time.
We offer a full spectrum of resources to meet the drug discovery and
development needs of the pharmaceutical and biotechnology industries. With
numerous facilities strategically located around the world, we apply advanced
scientific and technological expertise throughout the drug discovery and
development process - from lead optimization, pre-IND research, early clinical
research (bioequivalence, phases I-IIa) and bioanalysis through to global
clinical development (phases IIb-IV), central lab and centralized cardiac
services. For more information, visit our website at www.mdsps.com.
MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ),
a global life sciences company that provides market-leading products and
services that our customers need for the development of drugs and diagnosis
and treatment of disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging, radiotherapeutics,
and analytical instruments. MDS has more than 5,500 highly skilled people in
29 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24
hours a day.
For further information:
For further information: For Media: Charlene McGrady, (610) 239-7900
ext. 231, email@example.com; For Investors: Kim Lee, (416) 213-4721,